

Guido Alves

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7482514/guido-alves-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107 papers	5,947 citations	40 h-index	76 g-index
127 ext. papers	7,043 ext. citations	5.8 avg, IF	5.69 L-index

#	Paper	IF	Citations
107	GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.. <i>Movement Disorders</i> , 2022 ,	7	2
106	Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA.. <i>Epigenetics</i> , 2022 , 1-16	5.7	0
105	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 479-483	2.2	0
104	Parkinson's disease clinical milestones and mortality.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 58	9.7	0
103	Early Forms of β -Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson's Disease. <i>Biomolecules</i> , 2022 , 12, 747	5.9	1
102	CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211060337	3.7	2
101	Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. <i>Neurology</i> , 2021 , 96, e1036-e1044	6.5	6
100	Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. <i>Journal of Neurology</i> , 2021 , 1	5.5	2
99	Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. <i>Molecular Neurodegeneration</i> , 2021 , 16, 31	19	5
98	Early constipation predicts faster dementia onset in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021 , 7, 45	9.7	6
97	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <i>Nature Genetics</i> , 2021 , 53, 787-793	36.3	15
96	Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 1569-1578	5.3	0
95	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021 , 36, 106-117	7	16
94	Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2021 , 268, 1385-1394	5.5	6
93	Progression of fatigue in Parkinson's disease - a 9-year follow-up. <i>European Journal of Neurology</i> , 2021 , 28, 108-116	6	5
92	Letter to the editor in response to the letter from the EPIPARK Study Group regarding the publication 'Progression of fatigue in Parkinson's disease - a 9-year follow-up' (Eur J Neurol 2021. doi:10.1111/ene.14520). <i>European Journal of Neurology</i> , 2021 , 28, e33-e34	6	
91	A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021 , 7, 54	9.7	3

90	The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study. <i>Neuroscience Letters</i> , 2021 , 764, 136243	3.3	1
89	Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer's disease dementia and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041881	1.2	
88	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 76, 49-53	3.6	3
87	Differential transcript usage in the Parkinson's disease brain. <i>PLoS Genetics</i> , 2020 , 16, e1009182	6	9
86	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1087-1098	5.3	19
85	Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. <i>PLoS ONE</i> , 2020 , 15, e0239824	3.7	3
84	Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 27-30	3.6	4
83	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 2257-2263	5.6	11
82	Genetic risk scores and hallucinations in patients with Parkinson disease. <i>Neurology: Genetics</i> , 2020 , 6, e492	3.8	4
81	Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid. <i>Scientific Reports</i> , 2020 , 10, 22098	4.9	3
80	Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease. <i>Journal of Neurology</i> , 2020 , 267, 259-266	5.5	3
79	The value of cerebrospinal fluid β -synuclein and the tau/ β -synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. <i>European Journal of Neurology</i> , 2020 , 27, 43-50	6	5
78	Common gene expression signatures in Parkinson's disease are driven by changes in cell composition. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 55	7.3	16
77	Association of Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients. <i>Frontiers in Neurology</i> , 2020 , 11, 620585	4.1	1
76	Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts. <i>Neurology: Genetics</i> , 2019 , 5, e348	3.8	57
75	Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study. <i>Neurology</i> , 2019 , 93, e1526-e1534	6.5	29
74	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 202-210	3.6	19
73	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019 , 34, 1839-1850	7	69

72	Cellular Proteostasis in Neurodegeneration. <i>Molecular Neurobiology</i> , 2019 , 56, 3676-3689	6.2	79
71	A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 298-299	7	
70	No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. <i>Brain</i> , 2018 , 141, e16	11.2	3
69	Evolution of cerebrospinal fluid total β -synuclein in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 4-8	3.6	23
68	Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. <i>Neurobiology of Aging</i> , 2018 , 63, 120-127	5.6	27
67	Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. <i>Acta Neuropathologica</i> , 2018 , 135, 409-425	14.3	59
66	Is psychosis associated with impulse control disorders in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2018 , 53, 110-111	3.6	
65	Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. <i>Neuroscience Letters</i> , 2018 , 674, 123-126	3.3	7
64	Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 508-514	3.8	16
63	Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 109	4.1	18
62	Excessive Daytime Sleepiness and REM Sleep Behavior Disorders in Parkinson's Disease: A Narrative Review on Early Intervention With Implications to Neuroprotection. <i>Frontiers in Neurology</i> , 2018 , 9, 961	4.1	7
61	Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1591-1600	7	30
60	Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1293-1301	1.2	16
59	Inflammation and fatigue in early, untreated Parkinson's Disease. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 394-399	3.8	13
58	Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. <i>Neurology</i> , 2017 , 88, 767-774	6.5	106
57	Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 183-191	5.3	35
56	Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. <i>Journal of Neurology</i> , 2017 , 264, 364-372	5.5	17
55	Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration. <i>Molecular Neurobiology</i> , 2017 , 54, 7639-7655	6.2	8

54	Validation of a new assay for β -synuclein detection in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017 , 55, 254-260	5.9	5
53	Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. <i>Parkinsonism and Related Disorders</i> , 2017 , 42, 28-33	3.6	22
52	Risk and course of motor complications in a population-based incident Parkinson's disease cohort. <i>Parkinsonism and Related Disorders</i> , 2016 , 22, 48-53	3.6	61
51	microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. <i>Cellular and Molecular Life Sciences</i> , 2016 , 73, 811-27	10.3	69
50	Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016 , 2016, 1941034	2.6	12
49	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 121	5.3	10
48	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 147	5.3	23
47	LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. <i>Journal of Neuroscience Research</i> , 2016 , 94, 717-35	4.4	27
46	Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study. <i>Neurology</i> , 2016 , 87, 1599-1606	6.5	32
45	Parkinson's disease and age: The obvious but largely unexplored link. <i>Experimental Gerontology</i> , 2015 , 68, 33-8	4.5	55
44	Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population. <i>Parkinson's Disease</i> , 2015 , 2015, 973298	2.6	6
43	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD. <i>Neuroepidemiology</i> , 2015 , 45, 282-974	5.4	16
42	A 12-year population-based study of freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 254-8	3.6	68
41	A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. <i>PLoS ONE</i> , 2015 , 10, e0143969	3.7	19
40	New insight into neurodegeneration: the role of proteomics. <i>Molecular Neurobiology</i> , 2014 , 49, 1181-99	6.2	17
39	CSF A β 2 predicts early-onset dementia in Parkinson disease. <i>Neurology</i> , 2014 , 82, 1784-90	6.5	108
38	Cerebrospinal fluid A β levels correlate with structural brain changes in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 302-10	7	23
37	Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. <i>JAMA Neurology</i> , 2013 , 70, 580-6	17.2	222

36	Cerebrospinal fluid amyloid- β and phenotypic heterogeneity in de novo Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 537-43	5.5	48
35	Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 20, 142-8	6.5	47
34	Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012 , 33, 2113-24	5.6	51
33	Verbal memory in drug-naïve, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. <i>Neuropsychology</i> , 2011 , 25, 114-24	3.8	71
32	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 297-301	7	43
31	CSF amyloid β 8 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 160-4	5.5	38
30	The Arabidopsis DJ-1a protein confers stress protection through cytosolic SOD activation. <i>Journal of Cell Science</i> , 2010 , 123, 1644-51	5.3	77
29	CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1080-6	5.5	151
28	A 12-year population-based study of psychosis in Parkinson disease. <i>Archives of Neurology</i> , 2010 , 67, 996-1001		246
27	What predicts mortality in Parkinson disease?: a prospective population-based long-term study. <i>Neurology</i> , 2010 , 75, 1270-6	6.5	201
26	Epidemiology of psychosis in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2010 , 289, 12-7	3.2	231
25	Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology</i> , 2010 , 257, 217-23	5.5	73
24	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 629-33		52
23	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 805-22	7	152
22	APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009 , 22, 166-70	3.8	42
21	Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 1279-82	5.5	77
20	Brain atrophy and white matter hyperintensities in early Parkinson's disease(a). <i>Movement Disorders</i> , 2009 , 24, 2233-41	7	43
19	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology</i> , 2009 , 8, 613-8	24.1	358

18	Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 851-7	5.5	165
17	Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 295-9	3.6	108
16	Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. <i>Neurology</i> , 2009 , 72, 1121-6	6.5	488
15	The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 928-30	5.5	189
14	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. <i>NeuroImage</i> , 2009 , 47, 2083-9	7.9	54
13	Epidemiology of Parkinson's disease. <i>Journal of Neurology</i> , 2008 , 255 Suppl 5, 18-32	5.5	257
12	Predictors and course of health-related quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 1420-7	7	128
11	Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 559-63	2.6	40
10	Changes in motor subtype and risk for incident dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1123-30	7	320
9	Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?. <i>Neurology</i> , 2006 , 67, 853-8	6.5	151
8	Progression of motor impairment and disability in Parkinson disease: a population-based study. <i>Neurology</i> , 2005 , 65, 1436-41	6.5	196
7	Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. <i>Advances in Neurology</i> , 2005 , 96, 56-64		18
6	Is fatigue an independent and persistent symptom in patients with Parkinson disease?. <i>Neurology</i> , 2004 , 63, 1908-11	6.5	156
5	Cigarette smoking in Parkinson's disease: influence on disease progression. <i>Movement Disorders</i> , 2004 , 19, 1087-1092	7	62
4	Familial Parkinson's disease: a community-based study. <i>European Journal of Neurology</i> , 2003 , 10, 159-63	6	22
3	Common gene expression signatures in Parkinson's disease are driven by changes in cell composition		2
2	Genome-wide dysregulation of histone acetylation in the Parkinson's disease brain		2
1	Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA		1

